Provided by Tiger Trade Technology Pte. Ltd.

InflaRx N.V.

2.10
+0.08003.96%
Post-market: 2.06-0.0382-1.82%18:31 EDT
Volume:419.89K
Turnover:873.38K
Market Cap:309.32M
PE:-3.67
High:2.12
Open:2.03
Low:2.03
Close:2.02
52wk High:2.95
52wk Low:0.7984
Shares:147.29M
Float Shares:106.00M
Volume Ratio:0.51
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5715
EPS(LYR):-0.7963
ROE:-38.52%
ROA:-18.54%
PB:1.81
PE(LYR):-2.64

Loading ...

InflaRx Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 20

InflaRx price target lowered to $14 from $22 at Guggenheim

TIPRANKS
·
Mar 20

Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)

TIPRANKS
·
Mar 20

InflaRx NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 19

InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate

Benzinga Earnings
·
Mar 19

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

TIPRANKS
·
Mar 19

InflaRx FY 2025 net loss narrows 9.8% to EUR 45.63 million

Reuters
·
Mar 19

Press Release: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Dow Jones
·
Mar 19

InflaRx N.V. Director Mark Kubler Files Initial Statement of Beneficial Ownership

Reuters
·
Mar 18

InflaRx N.V. director Anthony S. Gibney files initial beneficial ownership statement

Reuters
·
Mar 18

InflaRx N.V. Director Hege Hellstrom Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting

Reuters
·
Mar 18

InflaRx N.V. Chief Scientific Officer Guo Renfeng files initial beneficial ownership statement

Reuters
·
Mar 18

InflaRx N.V. SVP Derval OCarroll Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

InflaRx CEO and Director Niels Riedemann Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

InflaRx NV CFO Thomas Taapken files initial beneficial ownership statement

Reuters
·
Mar 18

InflaRx to present Phase 3 vilobelimab data in pyoderma gangrenosum at AAD annual meeting

Reuters
·
Mar 18

InflaRx NV expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
Mar 17

InflaRx Receives Nasdaq Minimum Bid Price Deficiency Notice

Reuters
·
Mar 14

InflaRx NV to release full-year 2025 results

Reuters
·
Mar 12